KRAS and cancer: This may in part explain why HRAS-transformed cells remain within epithelia on stiff substrates [77], and it may also help to explain why tissue fibrosis is a risk factor in the development and progression of many RAS-driven cancers, including KRAS mutant PDAC [79].